In a move aimed at expanding affordable treatment options for millions of Americans living with diabetes, Biocon Biologics Ltd. and nonprofit generic drug manufacturer Civica, Inc. have announced a ...

Civica plans to distribute its insulin glargine to pharmacies across the United States for $45 for a box of five pens. “Through the partnership we formed with Civica more than six years ago, BCBSA and ...

Biocon Biologics Ltd., a unit of India’s Biocon Ltd., has expanded its partnership with US-based nonprofit Civica Inc. to launch a private-label version of insulin glargine in the United States, ...

Prescriptions for the insulin glargine biosimilar Semglee increased after it was granted interchangeable status with its reference product, Lantus. Increases were seen across retail, mail order, and ...

Gov. Gavin Newsom announced on Thursday that the first state-made insulin would be available at the start of 2026.California’s CalRx® Insulin Glargine in 3mL pen form will be $55 per five-pack. That's ...

California will begin offering its own brand of low-cost insulin in 2026, becoming the first state to contract for and sell an affordable version of the drug to residents, Gov. Gavin Newsom announced ...

LEHI, Utah, Oct. 16, 2025 /PRNewswire/ -- Non-profit pharmaceutical company Civica will launch an affordable long-acting insulin – insulin glargine-yfgn in pre-filled pens – at the lowest list price ...

A bond's coupon rate is fixed, specifying the annual payment relative to the bond's face value. Calculating bond coupon rate is straightforward: divide annual payments by the bond's face value. Yield ...

GoodRx, a resource for healthcare savings and information, is working with Sanofi, a company that specializes in diabetes care, to offer people living with diabetes access to Lantus (insulin glargine ...

GoodRx is teaming up with Sanofi to offer consumers access to its most prescribed insulin, Lantus, for $35 at thousands of pharmacies nationwide. All Americans with a valid prescription, regardless of ...

Oct 19 (Reuters) - GoodRx (GDRX.O), opens new tab said on Thursday it has collaborated with Sanofi (SASY.PA), opens new tab to offer the drugmaker's most-prescribed insulin injection Lantus for only ...